Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Varsha Gandhi, PhD, on Ibrutinib

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Dec
29
Today In Oncology
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo